Gsk3B Protein (Glycogen Synthase Kinase 3 Beta) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Gsk3B Protein (Glycogen Synthase Kinase 3 Beta) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
.infobox-protein
!! colspan="2" style="background:#f8f9fa; text-align:center; font-weight:bold" | GSK3B Protein (Glycogen Synthase Kinase 3 Beta)
|-
! Gene
! UniProt
! PDB Structures
| 1UV5, 1R0E, 3L1S, 4DIT, 5K5N |
|---|
! Molecular Weight
| ~47 kDa |
|---|
! Subcellular Localization
| Cytoplasm, Nucleus, Mitochondria |
|---|
! Protein Family
| Serine/Threonine Kinase |
|---|
GSK3B is a serine/threonine kinase with a unique structure containing an N-terminal kinase domain and a C-terminal regulatory region. The protein has a deep substrate binding pocket that recognizes the motif SXXXS(P), where phosphorylation of the serine residue inhibits activity.
GSK3B is a multifunctional serine/threonine kinase involved in numerous signaling pathways including Wnt, PI3K/Akt, mTOR, and MAPK. It phosphorylates over 100 substrates including glycogen synthase (hence its name), tau, beta-catenin, and transcription factors. In the brain, GSK3B regulates neuronal development, synaptic plasticity, and circadian rhythm.
GSK3B is centrally involved in neurodegenerative disease pathogenesis. In Alzheimer's disease, GSK3B hyperphosphorylates tau, promoting neurofibrillary tangle formation. It also regulates amyloid precursor protein (APP) processing and A-beta production. In Parkinson's disease, GSK3B contributes to alpha-synuclein phosphorylation and dopaminergic neuron death. Increased GSK3B activity is observed in AD, PD, and HD brains.
GSK3B inhibitors have been extensively investigated as AD therapeutics. Tideglusib (NP-12), a non-ATP-competitive inhibitor, reached clinical trials for AD. Other inhibitors include lithium (indirect), CHIR99021, and SB-216763. Challenges include brain penetration and safety concerns related to on-target effects on glycogen metabolism.
Gsk3B Protein (Glycogen Synthase Kinase 3 Beta) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Gsk3B Protein (Glycogen Synthase Kinase 3 Beta) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.